Misplaced Pages

CD4

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from CD4+) Marker on immune cells For other uses, see CD-4 (disambiguation).

CD4
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

1CDH, 1CDI, 1CDJ, 1CDU, 1CDY, 1G9M, 1G9N, 1GC1, 1JL4, 1Q68, 1RZJ, 1RZK, 1WIO, 1WIP, 1WIQ, 2B4C, 2JKR, 2JKT, 2KLU, 2NXY, 2NXZ, 2NY0, 2NY1, 2NY2, 2NY3, 2NY4, 2NY5, 2NY6, 2QAD, 3B71, 3CD4, 3JWD, 3JWO, 3LQA, 3O2D, 3S5L, 3T0E, 4JM2, 1WBR, 3S4S, 4H8W, 4P9H, 4Q6I, 4R2G, 4R4H, 4RQS, 3J70, 5A7X, 5A8H, 5CAY

Identifiers
AliasesCD4, CD4mut, CD4 molecule, OKT4D, IMD79
External IDsOMIM: 186940; MGI: 88335; HomoloGene: 513; GeneCards: CD4; OMA:CD4 - orthologs
Gene location (Human)
Chromosome 12 (human)
Chr.Chromosome 12 (human)
Chromosome 12 (human)Genomic location for CD4Genomic location for CD4
Band12p13.31Start6,786,858 bp
End6,820,799 bp
Gene location (Mouse)
Chromosome 6 (mouse)
Chr.Chromosome 6 (mouse)
Chromosome 6 (mouse)Genomic location for CD4Genomic location for CD4
Band6 F2|6 59.17 cMStart124,841,655 bp
End124,865,184 bp
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • granulocyte

  • monocyte

  • lymph node

  • spleen

  • appendix

  • gallbladder

  • thymus

  • upper lobe of left lung

  • right lung

  • right lobe of liver
Top expressed in
  • thymus

  • lymph node

  • mesenteric lymph nodes

  • blood

  • spleen

  • zygote

  • external carotid artery

  • internal carotid artery

  • superior frontal gyrus

  • molar
More reference expression data
BioGPS
n/a
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

920

12504

Ensembl

ENSG00000010610

ENSMUSG00000023274

UniProt

P01730

P06332

RefSeq (mRNA)
NM_000616
NM_001195014
NM_001195015
NM_001195016
NM_001195017

NM_001382705
NM_001382706
NM_001382707
NM_001382714

NM_013488

RefSeq (protein)
NP_000607
NP_001181943
NP_001181944
NP_001181945
NP_001181946

NP_001369634
NP_001369635
NP_001369636
NP_001369643

NP_038516

Location (UCSC)Chr 12: 6.79 – 6.82 MbChr 6: 124.84 – 124.87 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse
CD4, Cluster of differentiation 4, extracellular
structure of T cell surface glycoprotein cd4, monoclinic crystal form
Identifiers
SymbolCD4-extrcel
PfamPF09191
InterProIPR015274
SCOP21cid / SCOPe / SUPFAM
OPM superfamily193
OPM protein2klu
CDDcd07695
Membranome27
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Image of CD4 co-receptor binding to MHC (Major Histocompatibility Complex) non-polymorphic region.

In molecular biology, CD4 (cluster of differentiation 4) is a glycoprotein that serves as a co-receptor for the T-cell receptor (TCR). CD4 is found on the surface of immune cells such as helper T cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 (after the OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene.

CD4+ T helper cells are white blood cells that are an essential part of the human immune system. They are often referred to as CD4 cells, T helper cells or T4 cells. They are called helper cells because one of their main roles is to send signals to other types of immune cells, including CD8 killer cells, which then destroy the infectious particle. If CD4 cells become depleted, for example in untreated HIV infection, or following immune suppression prior to a transplant, the body is left vulnerable to a wide range of infections that it would otherwise have been able to fight.

Structure

Schematic representation of CD4 receptor.

Like many cell surface receptors/markers, CD4 is a member of the immunoglobulin superfamily.

It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell:

The immunoglobulin variable (IgV) domain of D1 adopts an immunoglobulin-like β-sandwich fold with seven β-strands in two β-sheets, in a Greek key topology.

CD4 interacts with the β2-domain of MHC class II molecules through its D1 domain. T cells displaying CD4 molecules (and not CD8) on their surface, therefore, are specific for antigens presented by MHC II and not by MHC class I (they are MHC class II-restricted). MHC class I contains Beta-2 microglobulin.

The short cytoplasmic/intracellular tail (C) of CD4 contains a special sequence of amino acids that allow it to recruit and interact with the tyrosine kinase Lck.

Function

CD4 is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The TCR complex and CD4 bind to distinct regions of the antigen-presenting MHC class II molecule. The extracellular D1 domain of CD4 binds to the β2 region of MHC class II. The resulting close proximity between the TCR complex and CD4 allows the tyrosine kinase Lck bound to the cytoplasmic tail of CD4 to phosphorylate tyrosine residues of immunoreceptor tyrosine activation motifs (ITAMs) on the cytoplasmic domains of CD3 to amplify the signal generated by the TCR. Phosphorylated ITAMs on CD3 recruit and activate SH2 domain-containing protein tyrosine kinases (PTK), such as ZAP70, to further mediate downstream signalling through tyrosine phosphorylation. These signals lead to the activation of transcription factors, including NF-κB, NFAT, AP-1, to promote T cell activation.

Conservation of their respective cytoplasmic tail motifs, CxC/H in the case of CD4 and an ITIM-like motif in the case of LAG-3, supports that competition between CD4 and LAG-3 for binding of kinase LCK is a conserved core part of the jawed vertebrate immune system.

CD4 is closely related to LAG-3, and together they form an evolutionary conserved system from the level of sharks competing for binding Lck by conserved motifs in their cytoplasmic tails: CD4 through a Cys-X-Cys/His motif and LAG-3 through an immunoreceptor tyrosine-based inhibition motif like (ITIM-like) motif. LAG-3, which is an inhibitory receptor, is upregulated in activated T cells as a kind of negative feedback loop.

Other interactions

CD4 has also been shown to interact with SPG21, and Uncoordinated-119 (Unc-119).

Disease

HIV infection

HIV-1 uses CD4 to gain entry into host T-cells and achieves this through its viral envelope protein known as gp120. The binding to CD4 creates a shift in the conformation of gp120 allowing HIV-1 to bind to a co-receptor expressed on the host cell. These co-receptors are chemokine receptors CCR5 or CXCR4. Following a structural change in another viral protein (gp41), HIV inserts a fusion peptide into the host cell that allows the outer membrane of the virus to fuse with the cell membrane.

HIV pathology

HIV infection leads to a progressive reduction in the number of T cells expressing CD4. Medical professionals refer to the CD4 count to decide when to begin treatment during HIV infection, although recent medical guidelines have changed to recommend treatment at all CD4 counts as soon as HIV is diagnosed. A CD4 count measures the number of T cells expressing CD4. While CD4 counts are not a direct HIV test—e.g. they do not check the presence of viral DNA, or specific antibodies against HIV—they are used to assess the immune system of a patient.

National Institutes of Health guidelines recommend treatment of any HIV-positive individuals, regardless of CD4 count Normal blood values are usually expressed as the number of cells per microliter (μL, or equivalently, cubic millimeter, mm) of blood, with normal values for CD4 cells being 500–1200 cells/mm. Patients often undergo treatments when the CD4 counts reach a level of 350 cells per microliter in Europe but usually around 500/μL in the US; people with less than 200 cells per microliter are at high risk of contracting AIDS defined illnesses. Medical professionals also refer to CD4 tests to determine efficacy of treatment.

Viral load testing provides more information about the efficacy for therapy than CD4 counts. For the first 2 years of HIV therapy, CD4 counts may be done every 3–6 months. If a patient's viral load becomes undetectable after 2 years then CD4 counts might not be needed if they are consistently above 500/mm. If the count remains at 300–500/mm, then the tests can be done annually. It is not necessary to schedule CD4 counts with viral load tests and the two should be done independently when each is indicated.

Reference ranges for blood tests of white blood cells, comparing CD4+ cell amount (shown in green-yellow) with other cells.

Other diseases

CD4 continues to be expressed in most neoplasms derived from T helper cells. It is therefore possible to use CD4 immunohistochemistry on tissue biopsy samples to identify most forms of peripheral T cell lymphoma and related malignant conditions. The antigen has also been associated with a number of autoimmune diseases such as vitiligo and type I diabetes mellitus.

T-cells play a large part in autoinflammatory diseases. When testing a drug's efficacy or studying diseases, it is helpful to quantify the amount of T-cells on fresh-frozen tissue with CD4+, CD8+, and CD3+ T-cell markers (which stain different markers on a T-cell – giving different results).

See also

References

  1. ^ GRCh38: Ensembl release 89: ENSG00000010610Ensembl, May 2017
  2. ^ GRCm38: Ensembl release 89: ENSMUSG00000023274Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Bernard A, Boumsell L, Hill C (1984). "Joint Report of the First International Workshop on Human Leucocyte Differentiation Antigens by the Investigators of the Participating Laboratories". In Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF (eds.). Leucocyte typing: human leucocyte differentiation antigens detected by monoclonal antibodies: specification, classification, nomenclature. Berlin: Springer. pp. 45–48. doi:10.1007/978-3-642-68857-7_3. ISBN 0-387-12056-4. Report on the first international references workshop sponsored by INSERM, WHO and IUIS
  6. Isobe M, Huebner K, Maddon PJ, Littman DR, Axel R, Croce CM (June 1986). "The gene encoding the T-cell surface protein T4 is located on human chromosome 12". Proceedings of the National Academy of Sciences of the United States of America. 83 (12): 4399–4402. Bibcode:1986PNAS...83.4399I. doi:10.1073/pnas.83.12.4399. PMC 323740. PMID 3086883.
  7. Ansari-Lari MA, Muzny DM, Lu J, Lu F, Lilley CE, Spanos S, et al. (April 1996). "A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13". Genome Research. 6 (4): 314–326. doi:10.1101/gr.6.4.314. PMID 8723724.
  8. Brady RL, Dodson EJ, Dodson GG, Lange G, Davis SJ, Williams AF, Barclay AN (May 1993). "Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains". Science. 260 (5110): 979–983. Bibcode:1993Sci...260..979B. doi:10.1126/science.8493535. PMID 8493535.
  9. Rudd CE, Trevillyan JM, Dasgupta JD, Wong LL, Schlossman SF (July 1988). "The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 85 (14): 5190–5194. Bibcode:1988PNAS...85.5190R. doi:10.1073/pnas.85.14.5190. PMC 281714. PMID 2455897.
  10. Barber EK, Dasgupta JD, Schlossman SF, Trevillyan JM, Rudd CE (May 1989). "The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex". Proceedings of the National Academy of Sciences of the United States of America. 86 (9): 3277–3281. Bibcode:1989PNAS...86.3277B. doi:10.1073/pnas.86.9.3277. PMC 287114. PMID 2470098.
  11. Owens JA, Punt J, Stranford SA, Jones PP (2013). Kuby Immunology (7th ed.). New York: W.H. Freeman. pp. 100–101. ISBN 978-14641-3784-6.
  12. Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T (May 1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–1405. doi:10.1084/jem.171.5.1393. PMC 2187904. PMID 1692078.
  13. ^ Takizawa F, Hashimoto K, Miyazawa R, Ohta Y, Veríssimo A, Flajnik MF, et al. (2023-12-21). "CD4 and LAG-3 from sharks to humans: related molecules with motifs for opposing functions". Frontiers in Immunology. 14: 1267743. doi:10.3389/fimmu.2023.1267743. PMC 10768021. PMID 38187381.
  14. Kim PW, Sun ZY, Blacklow SC, Wagner G, Eck MJ (September 2003). "A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8". Science. 301 (5640): 1725–1728. Bibcode:2003Sci...301.1725K. doi:10.1126/science.1085643. PMID 14500983. S2CID 32336829.
  15. Ohashi K, Takizawa F, Tokumaru N, Nakayasu C, Toda H, Fischer U, et al. (August 2010). "A molecule in teleost fish, related with human MHC-encoded G6F, has a cytoplasmic tail with ITAM and marks the surface of thrombocytes and in some fishes also of erythrocytes". Immunogenetics. 62 (8): 543–559. doi:10.1007/s00251-010-0460-1. PMID 20614118. S2CID 12282281.
  16. Maeda TK, Sugiura D, Okazaki IM, Maruhashi T, Okazaki T (April 2019). "Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation". The Journal of Biological Chemistry. 294 (15): 6017–6026. doi:10.1074/jbc.RA119.007455. PMC 6463702. PMID 30760527.
  17. Zeitlmann L, Sirim P, Kremmer E, Kolanus W (March 2001). "Cloning of ACP33 as a novel intracellular ligand of CD4". The Journal of Biological Chemistry. 276 (12): 9123–9132. doi:10.1074/jbc.M009270200. PMID 11113139.
  18. Gorska MM, Stafford SJ, Cen O, Sur S, Alam R (February 2004). "Unc119, a novel activator of Lck/Fyn, is essential for T cell activation". The Journal of Experimental Medicine. 199 (3): 369–379. doi:10.1084/jem.20030589. PMC 2211793. PMID 14757743.
  19. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (June 1998). "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody". Nature. 393 (6686): 648–659. Bibcode:1998Natur.393..648K. doi:10.1038/31405. PMC 5629912. PMID 9641677.
  20. "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents" (PDF). AIDSinfo. U.S. Department of Health & Human Services. 2013-02-13. Archived from the original (PDF) on 2013-10-29. Retrieved 2013-10-24.
  21. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, et al. (May 1992). "Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis". Clinical and Experimental Immunology. 88 (2): 243–252. doi:10.1111/j.1365-2249.1992.tb03068.x. PMC 1554313. PMID 1349272.
  22. ^ HIV Medicine Association (February 2016), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, HIV Medicine Association, retrieved 9 May 2016
  23. Cooper K, Leong AS (2003). Manual of diagnostic antibodies for immunohistology. London: Greenwich Medical Media. p. 65. ISBN 1-84110-100-1.
  24. Zamani M, Tabatabaiefar MA, Mosayyebi S, Mashaghi A, Mansouri P (July 2010). "Possible association of the CD4 gene polymorphism with vitiligo in an Iranian population". Clinical and Experimental Dermatology. 35 (5): 521–524. doi:10.1111/j.1365-2230.2009.03667.x. PMID 19843086. S2CID 10427963.
  25. Ciccarelli F, De Martinis M, Ginaldi L (2014). "An update on autoinflammatory diseases". Current Medicinal Chemistry. 21 (3): 261–269. doi:10.2174/09298673113206660303. PMC 3905709. PMID 24164192.
  26. "550280 – BD Biosciences". BD Biosciences. Becton Dickinson.

Further reading

External links

This article incorporates text from the public domain Pfam and InterPro: IPR015274
PDB gallery
  • 1cdh: STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES 1cdh: STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
  • 1cdi: STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES 1cdi: STRUCTURES OF AN HIV AND MHC BINDING FRAGMENT FROM HUMAN CD4 AS REFINED IN TWO CRYSTAL LATTICES
  • 1cdj: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 1cdj: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4
  • 1cdu: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL 1cdu: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH PHE 43 REPLACED BY VAL
  • 1cdy: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER 1cdy: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4 MUTANT WITH GLY 47 REPLACED BY SER
  • 1g9m: HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B 1g9m: HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
  • 1g9n: HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B 1g9n: HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
  • 1gc1: HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY 1gc1: HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY
  • 1jl4: CRYSTAL STRUCTURE OF THE HUMAN CD4 N-TERMINAL TWO DOMAIN FRAGMENT COMPLEXED TO A CLASS II MHC MOLECULE 1jl4: CRYSTAL STRUCTURE OF THE HUMAN CD4 N-TERMINAL TWO DOMAIN FRAGMENT COMPLEXED TO A CLASS II MHC MOLECULE
  • 1q68: Solution structure of T-cell surface glycoprotein CD4 and Proto-oncogene tyrosine-protein kinase LCK fragments 1q68: Solution structure of T-cell surface glycoprotein CD4 and Proto-oncogene tyrosine-protein kinase LCK fragments
  • 1rzj: HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B 1rzj: HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
  • 1rzk: HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B 1rzk: HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
  • 1wio: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM 1wio: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TETRAGONAL CRYSTAL FORM
  • 1wip: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM 1wip: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, MONOCLINIC CRYSTAL FORM
  • 1wiq: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TRIGONAL CRYSTAL FORM 1wiq: STRUCTURE OF T-CELL SURFACE GLYCOPROTEIN CD4, TRIGONAL CRYSTAL FORM
  • 2b4c: Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody 2b4c: Crystal structure of HIV-1 JR-FL gp120 core protein containing the third variable region (V3) complexed with CD4 and the X5 antibody
  • 2nxy: HIV-1 gp120 Envelope Glycoprotein(S334A) Complexed with CD4 and Antibody 17b 2nxy: HIV-1 gp120 Envelope Glycoprotein(S334A) Complexed with CD4 and Antibody 17b
  • 2nxz: HIV-1 gp120 Envelope Glycoprotein (T257S, S334A, S375W) Complexed with CD4 and Antibody 17b 2nxz: HIV-1 gp120 Envelope Glycoprotein (T257S, S334A, S375W) Complexed with CD4 and Antibody 17b
  • 2ny0: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, T257S, V275C, S334A, S375W, A433M) Complexed with CD4 and Antibody 17b 2ny0: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, T257S, V275C, S334A, S375W, A433M) Complexed with CD4 and Antibody 17b
  • 2ny1: HIV-1 gp120 Envelope Glycoprotein (I109C, T257S, S334A, S375W, Q428C) Complexed with CD4 and Antibody 17b 2ny1: HIV-1 gp120 Envelope Glycoprotein (I109C, T257S, S334A, S375W, Q428C) Complexed with CD4 and Antibody 17b
  • 2ny2: HIV-1 gp120 Envelope Glycoprotein (T123C, T257S, S334A, S375W, G431C) Complexed with CD4 and Antibody 17b 2ny2: HIV-1 gp120 Envelope Glycoprotein (T123C, T257S, S334A, S375W, G431C) Complexed with CD4 and Antibody 17b
  • 2ny3: HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E267C, S334A, S375W) Complexed with CD4 and Antibody 17b 2ny3: HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E267C, S334A, S375W) Complexed with CD4 and Antibody 17b
  • 2ny4: HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, S334A, S375W) Complexed with CD4 and Antibody 17b 2ny4: HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, S334A, S375W) Complexed with CD4 and Antibody 17b
  • 2ny5: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) Complexed with CD4 and Antibody 17b 2ny5: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) Complexed with CD4 and Antibody 17b
  • 2ny6: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) Complexed with CD4 and Antibody 17b 2ny6: HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) Complexed with CD4 and Antibody 17b
  • 3cd4: REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4 3cd4: REFINEMENT AND ANALYSIS OF THE FIRST TWO DOMAINS OF HUMAN CD4
Transmembrane receptors: immunoglobulin superfamily immune receptors
Antibody receptor:
Fc receptor
Epsilon (ε)
Gamma (γ)
Alpha (α)/mu (μ)
Secretory
Antigen receptor
B cells
Antigen receptor
Co-receptor
stimulate:
inhibit:
Accessory molecules
T cells
Ligands
Antigen receptor
Co-receptors
Accessory molecules
Cytokine receptor
Killer-cell IG-like receptors
Leukocyte IG-like receptors
Proteins: clusters of differentiation (see also list of human clusters of differentiation)
1–50
51–100
101–150
151–200
201–250
251–300
301–350
Cluster of differentiation by lineage
Lymphoid
B cell
T/NK
T cell
NK cell
All
All
Myeloid
CFU-GM/
Myelomonocyte
MEP
CFU-Meg
CFU-E
All (pan-myeloid)
Stem cell
Interleukin receptor modulators
IL-1
IL-2
IL-3
IL-4
IL-5
IL-6
IL-7
IL-8
  • See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
IL-9
IL-10
IL-11
IL-12
IL-13
IL-15
IL-17
IL-18
IL-20
IL-21
IL-22
IL-23
IL-27
IL-28
IL-31
IL1RL1
IL1RL2
Others
JAK
Others
Categories: